drugset / Trial / NCT00141284
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
Timeline
- Start
- 2005-10
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nelfinavir | Other / unclassified | 1250 mg | — |
| Background | Lamivudine | Other / unclassified | 150 mg | — |
| Background | Zidovudine | Small molecule | 300 mg | — |